Xtandi 40 MG tablet 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FGET4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $17,021.36 to DMS Pharmaceutical Group Inc. for 120 tablets of XTANDI 40 MG, an oncology medication used in prostate cancer treatment. This delivery order, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, represents a single transaction under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the DLA. The award was made without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain, particularly for Department of Defense healthcare operations.
This delivery order is executed under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion DLA acquisition strategy designed to optimize pharmaceutical supply chain management for military healthcare facilities worldwide. DMS Pharmaceutical Group holds a single-award IDC valued at $499,999,999 under this program, running through December 31, 2036, which authorizes the issuance of delivery orders for a comprehensive range of branded and generic prescription drugs, biologics, and medical consumables. The company's performance across multiple delivery orders and its established presence in the federal pharmaceutical supply chain since 2001 position it to fulfill the specialized pharmaceutical requirements of Department of Defense medical facilities globally.
Quick answers
Who was awarded contract SPE2DR26FGET4?
SPE2DR26FGET4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FGET4 worth?
The government has obligated $17,021 on SPE2DR26FGET4.
Is contract SPE2DR26FGET4 an order under another contract?
Yes. SPE2DR26FGET4 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGET4 competed?
The extent of competition for SPE2DR26FGET4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award